Drug intelligence / Profile preview

ScTIL-v2

Development stage: Preclinical
Lead developer: Beijing Chineo Medical Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ScTIL-v2 is a modified tumour-infiltrating lymphocyte (TIL) therapy developed as an immunologic cytotoxicity and T lymphocyte replacement drug. It is designed to enhance the anti-tumor immune response by isolating, expanding, and re-infusing autologous T cells that have infiltrated a patient's tumor. These modified TILs are intended to recognize and attack cancer cells more effectively than unmodified counterparts. The therapy represents an advanced form of cell-based immunotherapy for cancer treatment[2].

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on ScTIL-v2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ScTIL-v2.

Explore the full profile